tiprankstipranks
Trending News
More News >
Carl Zeiss Meditec (DE:AFX)
XETRA:AFX
Germany Market

Carl Zeiss Meditec (AFX) Stock Forecast & Price Target

Compare
88 Followers
See the Price Targets and Ratings of:

AFX Analyst Ratings

Hold
11Ratings
Hold
3 Buy
7 Hold
1 Sell
Based on 11 analysts giving stock ratings to
Carl
Zeiss Meditec
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AFX Stock 12 Month Forecast

Average Price Target

€64.17
▲(12.58%Upside)
Based on 11 Wall Street analysts offering 12 month price targets for Carl Zeiss Meditec in the last 3 months. The average price target is €64.17 with a high forecast of €86.50 and a low forecast of €41.00. The average price target represents a 12.58% change from the last price of €57.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"40":"€40","87":"€87","51.75":"€51.8","63.5":"€63.5","75.25":"€75.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":86.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€86.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":64.17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€64.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":41,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€41.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[40,51.75,63.5,75.25,87],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,54.85,57.284615384615385,59.71923076923077,62.15384615384615,64.58846153846154,67.02307692307693,69.45769230769231,71.8923076923077,74.32692307692308,76.76153846153846,79.19615384615385,81.63076923076923,84.06538461538462,{"y":86.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,54.85,55.566923076923075,56.283846153846156,57.00076923076923,57.71769230769231,58.434615384615384,59.151538461538465,59.86846153846154,60.58538461538462,61.30230769230769,62.019230769230774,62.73615384615385,63.45307692307692,{"y":64.17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,54.85,53.784615384615385,52.71923076923077,51.65384615384615,50.58846153846154,49.52307692307692,48.457692307692305,47.392307692307696,46.32692307692308,45.261538461538464,44.19615384615385,43.13076923076923,42.065384615384616,{"y":41,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":83.876,"date":1717200000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":65.644,"date":1719792000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":63.167,"date":1722470400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":64.257,"date":1725148800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":65.694,"date":1727740800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":56.776,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":56.429,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":45.103,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":58.51,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":59.501,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.75,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.1,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.85,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€86.50Average Price Target€64.17Lowest Price Target€41.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on DE:AFX
TipRanks AITipRanks
Not Ranked
TipRanks
€62
Hold
8.77%
Upside
Reiterated
06/20/25
Carl Zeiss Meditec's overall stock score is driven primarily by its strong financial performance, which is slightly offset by mixed technical indicators and a high valuation. The lack of significant earnings call data or corporate events limits the score impact from these areas.
UBS
Hold
Reiterated
06/27/25
UBS Sticks to Their Hold Rating for Carl Zeiss Meditec (0DHC)
Kepler Capital  Analyst forecast on DE:AFX
Oliver ReinbergKepler Capital
Kepler Capital
€59
Hold
3.51%
Upside
Reiterated
06/25/25
Kepler Capital Sticks to Its Hold Rating for Carl Zeiss Meditec (0DHC)
Berenberg Bank Analyst forecast on DE:AFX
Sam EnglandBerenberg Bank
Berenberg Bank
€65
Hold
14.04%
Upside
Reiterated
05/29/25
Berenberg Bank Keeps Their Hold Rating on Carl Zeiss Meditec (0DHC)
DZ BANK AG Analyst forecast on DE:AFX
Unknown AnalystDZ BANK AG
Not Ranked
DZ BANK AG
Hold
Reiterated
05/28/25
DZ BANK AG Keeps Their Hold Rating on Carl Zeiss Meditec (0DHC)
RBC Capital
€60
Hold
5.26%
Upside
Reiterated
05/27/25
Carl Zeiss Meditec (0DHC) Gets a Hold from RBC Capital
Bernstein
€71€74
Buy
29.82%
Upside
Reiterated
05/15/25
Bernstein Reaffirms Their Buy Rating on Carl Zeiss Meditec (0DHC)
Goldman Sachs Analyst forecast on DE:AFX
Richard FeltonGoldman Sachs
Goldman Sachs
€75€77
Buy
35.09%
Upside
Reiterated
05/14/25
Goldman Sachs Remains a Buy on Carl Zeiss Meditec (0DHC)
Hauck & Aufhaeuser Analyst forecast on DE:AFX
Alexander GalitsaHauck & Aufhaeuser
Hauck & Aufhaeuser
€86.5
Buy
51.75%
Upside
Reiterated
05/14/25
Hauck & Aufhaeuser Sticks to Its Buy Rating for Carl Zeiss Meditec (0DHC)
Deutsche Bank  Analyst forecast on DE:AFX
Falko FriedrichsDeutsche Bank
Deutsche Bank
€55
Hold
-3.51%
Downside
Reiterated
05/14/25
Carl Zeiss Meditec (0DHC) Receives a Hold from Deutsche Bank
J.P. Morgan Analyst forecast on DE:AFX
Anchal VermaJ.P. Morgan
J.P. Morgan
€41
Sell
-28.07%
Downside
Reiterated
05/13/25
J.P. Morgan Sticks to Their Sell Rating for Carl Zeiss Meditec (0DHC)
Stifel Nicolaus Analyst forecast on DE:AFX
Dylan Van HaaftenStifel Nicolaus
Stifel Nicolaus
€60
Hold
5.26%
Upside
Reiterated
05/13/25
Hold Rating for Carl Zeiss Meditec Amid Optimistic Chinese Market Outlook and Operational Challenges
HSBC
€66€54
Hold
-5.26%
Downside
Reiterated
12/17/24
Carl Zeiss Meditec AG (AFX:GR) (CZMWY) PT Lowered to EUR54 at HSBCHSBC analyst Sezgi Oezener lowered the price target on Carl Zeiss Meditec AG (AFX:GR) (OTC: CZMWY) to EUR54.00 (from EUR66.00) while maintaining a Hold rating.
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on DE:AFX
TipRanks AITipRanks
Not Ranked
TipRanks
€62
Hold
8.77%
Upside
Reiterated
06/20/25
Carl Zeiss Meditec's overall stock score is driven primarily by its strong financial performance, which is slightly offset by mixed technical indicators and a high valuation. The lack of significant earnings call data or corporate events limits the score impact from these areas.
UBS
Hold
Reiterated
06/27/25
UBS Sticks to Their Hold Rating for Carl Zeiss Meditec (0DHC)
Kepler Capital  Analyst forecast on DE:AFX
Oliver ReinbergKepler Capital
Kepler Capital
€59
Hold
3.51%
Upside
Reiterated
06/25/25
Kepler Capital Sticks to Its Hold Rating for Carl Zeiss Meditec (0DHC)
Berenberg Bank Analyst forecast on DE:AFX
Sam EnglandBerenberg Bank
Berenberg Bank
€65
Hold
14.04%
Upside
Reiterated
05/29/25
Berenberg Bank Keeps Their Hold Rating on Carl Zeiss Meditec (0DHC)
DZ BANK AG Analyst forecast on DE:AFX
Unknown AnalystDZ BANK AG
Not Ranked
DZ BANK AG
Hold
Reiterated
05/28/25
DZ BANK AG Keeps Their Hold Rating on Carl Zeiss Meditec (0DHC)
RBC Capital
€60
Hold
5.26%
Upside
Reiterated
05/27/25
Carl Zeiss Meditec (0DHC) Gets a Hold from RBC Capital
Bernstein
€71€74
Buy
29.82%
Upside
Reiterated
05/15/25
Bernstein Reaffirms Their Buy Rating on Carl Zeiss Meditec (0DHC)
Goldman Sachs Analyst forecast on DE:AFX
Richard FeltonGoldman Sachs
Goldman Sachs
€75€77
Buy
35.09%
Upside
Reiterated
05/14/25
Goldman Sachs Remains a Buy on Carl Zeiss Meditec (0DHC)
Hauck & Aufhaeuser Analyst forecast on DE:AFX
Alexander GalitsaHauck & Aufhaeuser
Hauck & Aufhaeuser
€86.5
Buy
51.75%
Upside
Reiterated
05/14/25
Hauck & Aufhaeuser Sticks to Its Buy Rating for Carl Zeiss Meditec (0DHC)
Deutsche Bank  Analyst forecast on DE:AFX
Falko FriedrichsDeutsche Bank
Deutsche Bank
€55
Hold
-3.51%
Downside
Reiterated
05/14/25
Carl Zeiss Meditec (0DHC) Receives a Hold from Deutsche Bank
J.P. Morgan Analyst forecast on DE:AFX
Anchal VermaJ.P. Morgan
J.P. Morgan
€41
Sell
-28.07%
Downside
Reiterated
05/13/25
J.P. Morgan Sticks to Their Sell Rating for Carl Zeiss Meditec (0DHC)
Stifel Nicolaus Analyst forecast on DE:AFX
Dylan Van HaaftenStifel Nicolaus
Stifel Nicolaus
€60
Hold
5.26%
Upside
Reiterated
05/13/25
Hold Rating for Carl Zeiss Meditec Amid Optimistic Chinese Market Outlook and Operational Challenges
HSBC
€66€54
Hold
-5.26%
Downside
Reiterated
12/17/24
Carl Zeiss Meditec AG (AFX:GR) (CZMWY) PT Lowered to EUR54 at HSBCHSBC analyst Sezgi Oezener lowered the price target on Carl Zeiss Meditec AG (AFX:GR) (OTC: CZMWY) to EUR54.00 (from EUR66.00) while maintaining a Hold rating.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Carl Zeiss Meditec

1 Month
xxx
Success Rate
18/33 ratings generated profit
55%
Average Return
+2.03%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 54.55% of your transactions generating a profit, with an average return of +2.03% per trade.
3 Months
xxx
Success Rate
15/33 ratings generated profit
45%
Average Return
-1.10%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 45.45% of your transactions generating a profit, with an average return of -1.10% per trade.
1 Year
Alexander GalitsaHauck & Aufhaeuser
Success Rate
8/33 ratings generated profit
24%
Average Return
-13.05%
reiterated a buy rating 2 months ago
Copying Alexander Galitsa's trades and holding each position for 1 Year would result in 24.24% of your transactions generating a profit, with an average return of -13.05% per trade.
2 Years
xxx
Success Rate
7/33 ratings generated profit
21%
Average Return
-22.66%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 21.21% of your transactions generating a profit, with an average return of -22.66% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AFX Analyst Recommendation Trends

Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
5
4
2
1
1
Buy
0
3
7
11
8
Hold
26
17
14
16
17
Sell
5
4
4
5
3
Strong Sell
0
0
0
0
0
total
36
28
27
33
29
In the current month, AFX has received 9 Buy Ratings, 17 Hold Ratings, and 3 Sell Ratings. AFX average Analyst price target in the past 3 months is 64.17.
Each month's total comprises the sum of three months' worth of ratings.

AFX Financial Forecast

AFX Earnings Forecast

Next quarter’s earnings estimate for AFX is €0.58 with a range of €0.49 to €0.68. The previous quarter’s EPS was €0.52. AFX beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.17% of the time in the same period. In the last calendar year AFX has Outperformed its overall industry.
Next quarter’s earnings estimate for AFX is €0.58 with a range of €0.49 to €0.68. The previous quarter’s EPS was €0.52. AFX beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.17% of the time in the same period. In the last calendar year AFX has Outperformed its overall industry.

AFX Sales Forecast

Next quarter’s sales forecast for AFX is €559.90M with a range of €541.15M to €595.54M. The previous quarter’s sales results were €1.05B. AFX beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.47% of the time in the same period. In the last calendar year AFX has Outperformed its overall industry.
Next quarter’s sales forecast for AFX is €559.90M with a range of €541.15M to €595.54M. The previous quarter’s sales results were €1.05B. AFX beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.47% of the time in the same period. In the last calendar year AFX has Outperformed its overall industry.

AFX Stock Forecast FAQ

What is DE:AFX’s average 12-month price target, according to analysts?
Based on analyst ratings, Carl Zeiss Meditec’s 12-month average price target is 64.17.
    What is DE:AFX’s upside potential, based on the analysts’ average price target?
    Carl Zeiss Meditec has 12.58% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Carl Zeiss Meditec a Buy, Sell or Hold?
          Carl Zeiss Meditec has a consensus rating of Hold, which is based on 3 buy ratings, 7 hold ratings and 1 sell ratings.
            What is Carl Zeiss Meditec’s share price target?
            The average share price target for Carl Zeiss Meditec is 64.17. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €86.50 ,and the lowest forecast is €41.00. The average share price target represents 12.58% Increase from the current price of €57.
              What do analysts say about Carl Zeiss Meditec?
              Carl Zeiss Meditec’s analyst rating consensus is a Hold. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of Carl Zeiss Meditec?
                To buy shares of DE:AFX, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis